-
1
-
-
84941331228
-
World Alzheimer report 2015: the global impact of dementia - an analysis of prevalence, incidence, cost and trends
-
[1] Prince, M., Wimo, A., Guerchet, M., Gemma-Claire, A., Wu, Y.-T., Prina, M., World Alzheimer report 2015: the global impact of dementia - an analysis of prevalence, incidence, cost and trends. Alzheimer's Dis. Int., 84, 2015, 10.1111/j.0963-7214.2004.00293.x.
-
(2015)
Alzheimer's Dis. Int.
, vol.84
-
-
Prince, M.1
Wimo, A.2
Guerchet, M.3
Gemma-Claire, A.4
Wu, Y.-T.5
Prina, M.6
-
2
-
-
84925880097
-
2015 Alzheimer's disease facts and figures
-
[2] Alzheimer's Association, 2015 Alzheimer's disease facts and figures. Alzheimers. Dement. 11 (2015), 332–384, 10.1016/j.jalz.2015.02.003.
-
(2015)
Alzheimers. Dement.
, vol.11
, pp. 332-384
-
-
Alzheimer's Association1
-
3
-
-
77952430689
-
Management of behavioral problems in Alzheimer's disease
-
[3] Gauthier, S., Cummings, J., Ballard, C., Brodaty, H., Grossberg, G., Robert, P., Lyketsos, C., Management of behavioral problems in Alzheimer's disease. Int. Psychogeriatr. 22 (2010), 346–372, 10.1017/S1041610209991505.
-
(2010)
Int. Psychogeriatr.
, vol.22
, pp. 346-372
-
-
Gauthier, S.1
Cummings, J.2
Ballard, C.3
Brodaty, H.4
Grossberg, G.5
Robert, P.6
Lyketsos, C.7
-
4
-
-
79952544426
-
Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study
-
[4] Okura, T., Plassman, B.L., Steffens, D.C., Llewellyn, D.J., Potter, G.G., Langa, K.M., Neuropsychiatric symptoms and the risk of institutionalization and death: the aging, demographics, and memory study. J. Am. Geriatr. Soc. 59 (2011), 473–481, 10.1111/j.1532-5415.2011.03314.x.
-
(2011)
J. Am. Geriatr. Soc.
, vol.59
, pp. 473-481
-
-
Okura, T.1
Plassman, B.L.2
Steffens, D.C.3
Llewellyn, D.J.4
Potter, G.G.5
Langa, K.M.6
-
5
-
-
84914815546
-
Cognitive and neuropsychiatric impairments in Alzheimer's disease: current treatment strategies
-
[5] Borisovskaya, A., Pascualy, M., Borson, S., Cognitive and neuropsychiatric impairments in Alzheimer's disease: current treatment strategies. Curr. Psychiatry Rep. 16 (2014), 1–9, 10.1007/s11920-014-0470-z.
-
(2014)
Curr. Psychiatry Rep.
, vol.16
, pp. 1-9
-
-
Borisovskaya, A.1
Pascualy, M.2
Borson, S.3
-
6
-
-
0033920019
-
The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease
-
[6] Cummings, J.L., The role of cholinergic agents in the management of behavioural disturbances in Alzheimer's disease. Int. J. Neuropsychopharmacol. 3 (2000), 21–29, 10.1017/S1461145700001917.
-
(2000)
Int. J. Neuropsychopharmacol.
, vol.3
, pp. 21-29
-
-
Cummings, J.L.1
-
7
-
-
84983032987
-
Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances, Center for Drug Evaluation and Research, Rockville, MD
-
Available at: (accessed 04.04.16.)
-
[7] U.S. Food and Drug Administration, Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances, Center for Drug Evaluation and Research, Rockville, MD. 2005 Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm053171 (accessed 04.04.16.).
-
(2005)
-
-
U.S. Food and Drug Administration1
-
8
-
-
84983029883
-
Information on Conventional Antipsychotics, Center for Drug Evaluation and Research, Rockville, MD
-
Available at: accessed 04.04.16.
-
[8] U.S. Food and Drug Administration, Information on Conventional Antipsychotics, Center for Drug Evaluation and Research, Rockville, MD. 2008 Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm107211.htm accessed 04.04.16.
-
(2008)
-
-
U.S. Food and Drug Administration1
-
9
-
-
0011162190
-
Selective loss of central cholinergic neurons in Alzheimer's disease
-
[9] Davies, P., Maloney, A.J., Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet, 2, 1976, 1403, 10.1016/S0140-6736(76)91936-X.
-
(1976)
Lancet
, vol.2
, pp. 1403
-
-
Davies, P.1
Maloney, A.J.2
-
10
-
-
79955738773
-
The history of the cholinergic hypothesis, Behav
-
[10] Contestabile, A., The history of the cholinergic hypothesis, Behav. Brain Res. 221 (2011), 334–340, 10.1016/j.bbr.2009.12.044.
-
(2011)
Brain Res.
, vol.221
, pp. 334-340
-
-
Contestabile, A.1
-
11
-
-
80052921123
-
Alzheimer's disease: emerging trends in small molecule therapies
-
[11] Mohamed, T., Rao, P.P.N., Alzheimer's disease: emerging trends in small molecule therapies. Curr. Med. Chem. 18 (2011), 4299–4320, 10.2174/092986711797200435.
-
(2011)
Curr. Med. Chem.
, vol.18
, pp. 4299-4320
-
-
Mohamed, T.1
Rao, P.P.N.2
-
12
-
-
84860891561
-
Cholinesterase inhibitors and memantine for symptomatic treatment of dementia
-
e2986–e2986
-
[12] Rodda, J., Carter, J., Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ, 344, 2012, 10.1136/bmj.e2986 e2986–e2986.
-
(2012)
BMJ
, vol.344
-
-
Rodda, J.1
Carter, J.2
-
13
-
-
27144524511
-
Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease
-
[13] Grossberg, G.T., Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease. Curr. Med. Res. Opin. 21 (2005), 1631–1639, 10.1185/030079905X65402.
-
(2005)
Curr. Med. Res. Opin.
, vol.21
, pp. 1631-1639
-
-
Grossberg, G.T.1
-
14
-
-
84901826580
-
Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status
-
[14] Ramirez, M.J., Lai, M.K.P., Tordera, R.M., Francis, P.T., Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status. Drugs 74 (2014), 729–736, 10.1007/s40265-014-0217-5.
-
(2014)
Drugs
, vol.74
, pp. 729-736
-
-
Ramirez, M.J.1
Lai, M.K.P.2
Tordera, R.M.3
Francis, P.T.4
-
15
-
-
84907001204
-
Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment
-
[15] Lecoutey, C., Hedou, D., Freret, T., Giannoni, P., Gaven, F., Since, M., Bouet, V., Ballandonne, C., Corvaisier, S., Malzert Fréon, A., Mignani, S., Cresteil, T., Boulouard, M., Claeysen, S., Rochais, C., Dallemagne, P., Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E3825–E3830, 10.1073/pnas.1410315111.
-
(2014)
Proc. Natl. Acad. Sci. U. S. A.
, vol.111
, pp. E3825-E3830
-
-
Lecoutey, C.1
Hedou, D.2
Freret, T.3
Giannoni, P.4
Gaven, F.5
Since, M.6
Bouet, V.7
Ballandonne, C.8
Corvaisier, S.9
Malzert Fréon, A.10
Mignani, S.11
Cresteil, T.12
Boulouard, M.13
Claeysen, S.14
Rochais, C.15
Dallemagne, P.16
-
16
-
-
84920128903
-
Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease
-
[16] Benhamú, B., Martín-Fontecha, M., Vázquez-Villa, H., Pardo, L., López-Rodríguez, M.L., Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease. J. Med. Chem. 57 (2014), 7160–7181, 10.1021/jm5003952.
-
(2014)
J. Med. Chem.
, vol.57
, pp. 7160-7181
-
-
Benhamú, B.1
Martín-Fontecha, M.2
Vázquez-Villa, H.3
Pardo, L.4
López-Rodríguez, M.L.5
-
17
-
-
80052184853
-
Role of serotonin in Alzheimer's disease: a new therapeutic target?
-
[17] Geldenhuys, W.J., Van der Schyf, C.J., Role of serotonin in Alzheimer's disease: a new therapeutic target?. CNS Drugs 25 (2011), 765–781, 10.2165/11590190-000000000-00000.
-
(2011)
CNS Drugs
, vol.25
, pp. 765-781
-
-
Geldenhuys, W.J.1
Van der Schyf, C.J.2
-
18
-
-
13344275875
-
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor
-
[18] Kohen, R., Metcalf, M.A., Khan, N., Druck, T., Huebner, K., Lachowicz, J.E., Meltzer, H.Y., Sibley, D.R., Roth, B.L., Hamblin, M.W., Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J. Neurochem. 66 (2002), 47–56, 10.1046/j.1471-4159.1996.66010047.x.
-
(2002)
J. Neurochem.
, vol.66
, pp. 47-56
-
-
Kohen, R.1
Metcalf, M.A.2
Khan, N.3
Druck, T.4
Huebner, K.5
Lachowicz, J.E.6
Meltzer, H.Y.7
Sibley, D.R.8
Roth, B.L.9
Hamblin, M.W.10
-
19
-
-
0032819492
-
Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors
-
[19] Hamon, M., Doucet, E., Lefèvre, K., Miquel, M.C., Lanfumey, L., Insausti, R., Frechilla, D., Del Rio, J., Vergé, D., Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors. Neuropsychopharmacology 21 (1999), 68S–76S, 10.1016/S0893-133X(99)00044-5.
-
(1999)
Neuropsychopharmacology
, vol.21
, pp. 68S-76S
-
-
Hamon, M.1
Doucet, E.2
Lefèvre, K.3
Miquel, M.C.4
Lanfumey, L.5
Insausti, R.6
Frechilla, D.7
Del Rio, J.8
Vergé, D.9
-
20
-
-
79953706861
-
5-HT(6) receptor and cognition
-
[20] Codony, X., Vela, J.M., Ramírez, M.J., 5-HT(6) receptor and cognition. Curr. Opin. Pharmacol. 11 (2011), 94–100, 10.1016/j.coph.2011.01.004.
-
(2011)
Curr. Opin. Pharmacol.
, vol.11
, pp. 94-100
-
-
Codony, X.1
Vela, J.M.2
Ramírez, M.J.3
-
21
-
-
28044437798
-
5-HT6 receptors: a novel target for cognitive enhancement
-
[21] Mitchell, E.S., Neumaier, J.F., 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol. Ther. 108 (2005), 320–333, 10.1016/j.pharmthera.2005.05.001.
-
(2005)
Pharmacol. Ther.
, vol.108
, pp. 320-333
-
-
Mitchell, E.S.1
Neumaier, J.F.2
-
22
-
-
53449090731
-
An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function
-
[22] Fone, K.C.F., An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology 55 (2008), 1015–1022, 10.1016/j.neuropharm.2008.06.061.
-
(2008)
Neuropharmacology
, vol.55
, pp. 1015-1022
-
-
Fone, K.C.F.1
-
23
-
-
0037468873
-
Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist
-
[23] Riemer, C., Borroni, E., Levet-Trafit, B., Martin, J.R., Poli, S., Porter, R.H.P., Bös, M., Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J. Med. Chem. 46 (2003), 1273–1276, 10.1021/jm021085c.
-
(2003)
J. Med. Chem.
, vol.46
, pp. 1273-1276
-
-
Riemer, C.1
Borroni, E.2
Levet-Trafit, B.3
Martin, J.R.4
Poli, S.5
Porter, R.H.P.6
Bös, M.7
-
24
-
-
33748751956
-
Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release
-
[24] Marcos, B., Gil-Bea, F.J., Hirst, W.D., García-Alloza, M., Ramírez, M.J., Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur. J. Neurosci. 24 (2006), 1299–1306, 10.1111/j.1460-9568.2006.05003.x.
-
(2006)
Eur. J. Neurosci.
, vol.24
, pp. 1299-1306
-
-
Marcos, B.1
Gil-Bea, F.J.2
Hirst, W.D.3
García-Alloza, M.4
Ramírez, M.J.5
-
25
-
-
0034782825
-
The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus
-
[25] Dawson, L.A., Nguyen, H.Q., Li, P., The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25 (2001), 662–668, 10.1016/S0893-133X(01)00265-2.
-
(2001)
Neuropsychopharmacology
, vol.25
, pp. 662-668
-
-
Dawson, L.A.1
Nguyen, H.Q.2
Li, P.3
-
26
-
-
42049114860
-
Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466
-
[26] Schechter, L.E., Lin, Q., Smith, D.L., Zhang, G., Shan, Q., Platt, B., Brandt, M.R., Dawson, L.A., Cole, D., Bernotas, R., Robichaud, A., Rosenzweig-Lipson, S., Beyer, C.E., Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 33 (2008), 1323–1335, 10.1038/sj.npp.1301503.
-
(2008)
Neuropsychopharmacology
, vol.33
, pp. 1323-1335
-
-
Schechter, L.E.1
Lin, Q.2
Smith, D.L.3
Zhang, G.4
Shan, Q.5
Platt, B.6
Brandt, M.R.7
Dawson, L.A.8
Cole, D.9
Bernotas, R.10
Robichaud, A.11
Rosenzweig-Lipson, S.12
Beyer, C.E.13
-
27
-
-
84862856870
-
The Serotonin-6 receptor as a novel therapeutic target
-
[27] Yun, H.-M., Rhim, H., The Serotonin-6 receptor as a novel therapeutic target. Exp. Neurobiol., 20, 2011, 159, 10.5607/en.2011.20.4.159.
-
(2011)
Exp. Neurobiol.
, vol.20
, pp. 159
-
-
Yun, H.-M.1
Rhim, H.2
-
28
-
-
0034742606
-
A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze
-
[28] Woolley, M., Bentley, J., Sleight, A., Marsden, C., Fone, K.C., A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 41 (2001), 210–219, 10.1016/S0028-3908(01)00056-9.
-
(2001)
Neuropharmacology
, vol.41
, pp. 210-219
-
-
Woolley, M.1
Bentley, J.2
Sleight, A.3
Marsden, C.4
Fone, K.C.5
-
29
-
-
70349734329
-
Activation of the 5-HT6 receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus
-
[29] West, P.J., Marcy, V.R., Marino, M.J., Schaffhauser, H., Activation of the 5-HT6 receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus. Neuroscience 164 (2009), 692–701, 10.1016/j.neuroscience.2009.07.061.
-
(2009)
Neuroscience
, vol.164
, pp. 692-701
-
-
West, P.J.1
Marcy, V.R.2
Marino, M.J.3
Schaffhauser, H.4
-
30
-
-
0037343932
-
Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks
-
[30] Myhrer, T., Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Res. Rev. 41 (2003), 268–287, 10.1016/S0165-0173(02)00268-0.
-
(2003)
Brain Res. Rev.
, vol.41
, pp. 268-287
-
-
Myhrer, T.1
-
31
-
-
77957983253
-
Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data
-
[31] Wesołowska, A., Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data. Pharmacol. Rep. 62 (2010), 564–577, 10.1016/S1734-1140(10)70315-7.
-
(2010)
Pharmacol. Rep.
, vol.62
, pp. 564-577
-
-
Wesołowska, A.1
-
32
-
-
84931828604
-
Serotonergic 5-HT6 receptor antagonists: heterocyclic chemistry and potential therapeutic significance
-
[32] Bali, A., Singh, S., Serotonergic 5-HT6 receptor antagonists: heterocyclic chemistry and potential therapeutic significance. Curr. Top. Med. Chem. 15 (2015), 1643–1662, 10.2174/1568026615666150427110420.
-
(2015)
Curr. Top. Med. Chem.
, vol.15
, pp. 1643-1662
-
-
Bali, A.1
Singh, S.2
-
33
-
-
46749118971
-
5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease
-
[33] Upton, N., Chuang, T.T., Hunter, A.J., Virley, D.J., 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease. Neurotherapeutics 5 (2008), 458–469, 10.1016/j.nurt.2008.05.008.
-
(2008)
Neurotherapeutics
, vol.5
, pp. 458-469
-
-
Upton, N.1
Chuang, T.T.2
Hunter, A.J.3
Virley, D.J.4
-
34
-
-
84907995546
-
Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial
-
[34] Wilkinson, D., Windfeld, K., Colding-Jørgensen, E., Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. Neurol. 13 (2014), 1092–1099, 10.1016/S1474-4422(14)70198-X.
-
(2014)
Lancet. Neurol.
, vol.13
, pp. 1092-1099
-
-
Wilkinson, D.1
Windfeld, K.2
Colding-Jørgensen, E.3
-
35
-
-
27144449695
-
Designed multiple ligands. An emerging drug discovery paradigm
-
[35] Morphy, R., Rankovic, Z., Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48 (2005), 6523–6543, 10.1021/jm058225d.
-
(2005)
J. Med. Chem.
, vol.48
, pp. 6523-6543
-
-
Morphy, R.1
Rankovic, Z.2
-
36
-
-
3242794178
-
From magic bullets to designed multiple ligands
-
[36] Morphy, R., Kay, C., Rankovic, Z., From magic bullets to designed multiple ligands. Drug Discov. Today 9 (2004), 641–651, 10.1016/S1359-6446(04)03163-0.
-
(2004)
Drug Discov. Today
, vol.9
, pp. 641-651
-
-
Morphy, R.1
Kay, C.2
Rankovic, Z.3
-
37
-
-
84928684146
-
Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease
-
[37] Guzior, N., Więckowska, A., Panek, D., Malawska, B., Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease. Curr. Med. Chem. 22 (2015), 373–404, 10.2174/0929867321666141106122628.
-
(2015)
Curr. Med. Chem.
, vol.22
, pp. 373-404
-
-
Guzior, N.1
Więckowska, A.2
Panek, D.3
Malawska, B.4
-
38
-
-
84937758940
-
Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo
-
[38] Więckowska, A., Więckowski, K., Bajda, M., Brus, B., Sałat, K., Czerwińska, P., Gobec, S., Filipek, B., Malawska, B., Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with β-amyloid anti-aggregation properties and beneficial effects on memory in vivo. Bioorg. Med. Chem. 23 (2015), 2445–2457, 10.1016/j.bmc.2015.03.051.
-
(2015)
Bioorg. Med. Chem.
, vol.23
, pp. 2445-2457
-
-
Więckowska, A.1
Więckowski, K.2
Bajda, M.3
Brus, B.4
Sałat, K.5
Czerwińska, P.6
Gobec, S.7
Filipek, B.8
Malawska, B.9
-
39
-
-
84875061394
-
Structure-based search for new inhibitors of cholinesterases
-
[39] Bajda, M., Więckowska, A., Hebda, M., Guzior, N., Sotriffer, C.A., Malawska, B., Structure-based search for new inhibitors of cholinesterases. Int. J. Mol. Sci. 14 (2013), 5608–5632, 10.3390/ijms14035608.
-
(2013)
Int. J. Mol. Sci.
, vol.14
, pp. 5608-5632
-
-
Bajda, M.1
Więckowska, A.2
Hebda, M.3
Guzior, N.4
Sotriffer, C.A.5
Malawska, B.6
-
40
-
-
78649329701
-
Novel alkyl- and arylcarbamate derivatives with N-benzylpiperidine and N-benzylpiperazine moieties as cholinesterases inhibitors
-
[40] Więckowska, A., Bajda, M., Guzior, N., Malawska, B., Novel alkyl- and arylcarbamate derivatives with N-benzylpiperidine and N-benzylpiperazine moieties as cholinesterases inhibitors. Eur. J. Med. Chem. 45 (2010), 5602–5611, 10.1016/j.ejmech.2010.09.010.
-
(2010)
Eur. J. Med. Chem.
, vol.45
, pp. 5602-5611
-
-
Więckowska, A.1
Bajda, M.2
Guzior, N.3
Malawska, B.4
-
41
-
-
84902469833
-
Novel arylsulfonamide derivatives with 5-HT6/5-HT7 receptor antagonism targeting behavioral and psychological symptoms of dementia
-
[41] Kołaczkowski, M., Marcinkowska, M., Bucki, A., Pawłowski, M., Mitka, K., Jaśkowska, J., Kowalski, P., Kazek, G., Siwek, A., Wasik, A., Wesołowska, A., Mierzejewski, P., Bienkowski, P., Novel arylsulfonamide derivatives with 5-HT6/5-HT7 receptor antagonism targeting behavioral and psychological symptoms of dementia. J. Med. Chem. 57 (2014), 4543–4557, 10.1021/jm401895u.
-
(2014)
J. Med. Chem.
, vol.57
, pp. 4543-4557
-
-
Kołaczkowski, M.1
Marcinkowska, M.2
Bucki, A.3
Pawłowski, M.4
Mitka, K.5
Jaśkowska, J.6
Kowalski, P.7
Kazek, G.8
Siwek, A.9
Wasik, A.10
Wesołowska, A.11
Mierzejewski, P.12
Bienkowski, P.13
-
42
-
-
84928941584
-
Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia
-
[42] Kołaczkowski, M., Marcinkowska, M., Bucki, A., Śniecikowska, J., Pawłowski, M., Kazek, G., Siwek, A., Jastrzębska-Więsek, M., Partyka, A., Wasik, A., Wesołowska, A., Mierzejewski, P., Bienkowski, P., Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia. Eur. J. Med. Chem. 92 (2015), 221–235, 10.1016/j.ejmech.2014.12.045.
-
(2015)
Eur. J. Med. Chem.
, vol.92
, pp. 221-235
-
-
Kołaczkowski, M.1
Marcinkowska, M.2
Bucki, A.3
Śniecikowska, J.4
Pawłowski, M.5
Kazek, G.6
Siwek, A.7
Jastrzębska-Więsek, M.8
Partyka, A.9
Wasik, A.10
Wesołowska, A.11
Mierzejewski, P.12
Bienkowski, P.13
-
43
-
-
84983063884
-
1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 Ligands
-
US Application WO0236562 (A2)
-
[43] Kelly, M., Cole, D., 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 Ligands. 2002 US Application WO0236562 (A2).
-
(2002)
-
-
Kelly, M.1
Cole, D.2
-
44
-
-
0034284410
-
Huperzine A and tacrine attenuate β-amyloid peptide-induced oxidative injury
-
5<564::AID-JNR11>3.0.CO;2-X
-
[44] Xiao, X.Q., Wang, R., Tang, X.C., Huperzine A and tacrine attenuate β-amyloid peptide-induced oxidative injury. J. Neurosci. Res. 61 (2000), 564–569, 10.1002/1097-4547(20000901)61 5<564::AID-JNR11>3.0.CO;2-X.
-
(2000)
J. Neurosci. Res.
, vol.61
, pp. 564-569
-
-
Xiao, X.Q.1
Wang, R.2
Tang, X.C.3
-
45
-
-
35748931165
-
A new acetylcholinesterase inhibitor with anti-PAF activity modulates oxidative stress and pro-inflammatory mediators release in stimulated RAW 264.7 macrophage cells. Comparison with tacrine
-
[45] Ezoulin, M.J.M., Liu, Z., Dutertre-Catella, H., Wu, G., Dong, C.Z., Heymans, F., Ombetta, J.E., Rat, P., Massicot, F., A new acetylcholinesterase inhibitor with anti-PAF activity modulates oxidative stress and pro-inflammatory mediators release in stimulated RAW 264.7 macrophage cells. Comparison with tacrine. Int. Immunopharmacol. 7 (2007), 1685–1694, 10.1016/j.intimp.2007.08.023.
-
(2007)
Int. Immunopharmacol.
, vol.7
, pp. 1685-1694
-
-
Ezoulin, M.J.M.1
Liu, Z.2
Dutertre-Catella, H.3
Wu, G.4
Dong, C.Z.5
Heymans, F.6
Ombetta, J.E.7
Rat, P.8
Massicot, F.9
-
46
-
-
84939200016
-
Novel levetiracetam derivatives that are effective against the Alzheimer-like phenotype in mice: synthesis, in vitro, ex vivo, and in vivo efficacy studies
-
[46] Sola, I., Aso, E., Frattini, D., López-González, I., Espargaró, A., Sabaté, R., Di Pietro, O., Luque, F.J., Clos, M.V., Ferrer, I., Muñoz-Torrero, D., Novel levetiracetam derivatives that are effective against the Alzheimer-like phenotype in mice: synthesis, in vitro, ex vivo, and in vivo efficacy studies. J. Med. Chem. 58 (2015), 6018–6032, 10.1021/acs.jmedchem.5b00624.
-
(2015)
J. Med. Chem.
, vol.58
, pp. 6018-6032
-
-
Sola, I.1
Aso, E.2
Frattini, D.3
López-González, I.4
Espargaró, A.5
Sabaté, R.6
Di Pietro, O.7
Luque, F.J.8
Clos, M.V.9
Ferrer, I.10
Muñoz-Torrero, D.11
-
47
-
-
84906888262
-
Synthesis and biological evaluation of novel tacrine derivatives and tacrine-coumarin hybrids as cholinesterase inhibitors
-
[47] Hamulakova, S., Janovec, L., Hrabinova, M., Spilovska, K., Korabecny, J., Kristian, P., Kuca, K., Imrich, J., Synthesis and biological evaluation of novel tacrine derivatives and tacrine-coumarin hybrids as cholinesterase inhibitors. J. Med. Chem. 57 (2014), 7073–7084, 10.1021/jm5008648.
-
(2014)
J. Med. Chem.
, vol.57
, pp. 7073-7084
-
-
Hamulakova, S.1
Janovec, L.2
Hrabinova, M.3
Spilovska, K.4
Korabecny, J.5
Kristian, P.6
Kuca, K.7
Imrich, J.8
-
48
-
-
84908375105
-
Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects
-
[48] Nepovimova, E., Uliassi, E., Korabecny, J., Peña-Altamira, L.E., Samez, S., Pesaresi, A., Garcia, G.E., Bartolini, M., Andrisano, V., Bergamini, C., Fato, R., Lamba, D., Roberti, M., Kuca, K., Monti, B., Bolognesi, M.L., Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects. J. Med. Chem. 57 (2014), 8576–8589, 10.1021/jm5010804.
-
(2014)
J. Med. Chem.
, vol.57
, pp. 8576-8589
-
-
Nepovimova, E.1
Uliassi, E.2
Korabecny, J.3
Peña-Altamira, L.E.4
Samez, S.5
Pesaresi, A.6
Garcia, G.E.7
Bartolini, M.8
Andrisano, V.9
Bergamini, C.10
Fato, R.11
Lamba, D.12
Roberti, M.13
Kuca, K.14
Monti, B.15
Bolognesi, M.L.16
-
49
-
-
84856914519
-
New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties
-
[49] Fernández-Bachiller, M.I., Pérez, C., Monjas, L., Rademann, J., Rodríguez-Franco, M.I., New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties. J. Med. Chem. 55 (2012), 1303–1317, 10.1021/jm201460y.
-
(2012)
J. Med. Chem.
, vol.55
, pp. 1303-1317
-
-
Fernández-Bachiller, M.I.1
Pérez, C.2
Monjas, L.3
Rademann, J.4
Rodríguez-Franco, M.I.5
-
50
-
-
84856378492
-
Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases
-
[50] Galdeano, C., Viayna, E., Sola, I., Formosa, X., Camps, P., Badia, A., Clos, M.V., Relat, J., Ratia, M., Bartolini, M., Mancini, F., Andrisano, V., Salmona, M., Minguillón, C., González-Muñoz, G.C., Rodríguez-Franco, M.I., Bidon-Chanal, A., Luque, F.J., Muñoz-Torrero, D., Huprine-tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer's and prion diseases. J. Med. Chem. 55 (2012), 661–669, 10.1021/jm200840c.
-
(2012)
J. Med. Chem.
, vol.55
, pp. 661-669
-
-
Galdeano, C.1
Viayna, E.2
Sola, I.3
Formosa, X.4
Camps, P.5
Badia, A.6
Clos, M.V.7
Relat, J.8
Ratia, M.9
Bartolini, M.10
Mancini, F.11
Andrisano, V.12
Salmona, M.13
Minguillón, C.14
González-Muñoz, G.C.15
Rodríguez-Franco, M.I.16
Bidon-Chanal, A.17
Luque, F.J.18
Muñoz-Torrero, D.19
-
51
-
-
84925444000
-
Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease
-
[51] Xie, S.-S., Wang, X., Jiang, N., Yu, W., Wang, K.D.G., Lan, J.-S., Li, Z.-R., Kong, L.-Y., Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease. Eur. J. Med. Chem. 95 (2015), 153–165, 10.1016/j.ejmech.2015.03.040.
-
(2015)
Eur. J. Med. Chem.
, vol.95
, pp. 153-165
-
-
Xie, S.-S.1
Wang, X.2
Jiang, N.3
Yu, W.4
Wang, K.D.G.5
Lan, J.-S.6
Li, Z.-R.7
Kong, L.-Y.8
-
52
-
-
84887888271
-
Multifunctional tacrine derivatives in Alzheimer's disease
-
[52] Minarini, A., Milelli, A., Simoni, E., Rosini, M., Bolognesi, M.L., Marchetti, C., Tumiatti, V., Multifunctional tacrine derivatives in Alzheimer's disease. Curr. Top. Med. Chem. 13 (2013), 1771–1786, 10.2174/15680266113139990136.
-
(2013)
Curr. Top. Med. Chem.
, vol.13
, pp. 1771-1786
-
-
Minarini, A.1
Milelli, A.2
Simoni, E.3
Rosini, M.4
Bolognesi, M.L.5
Marchetti, C.6
Tumiatti, V.7
-
53
-
-
84861048527
-
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors
-
[53] Chen, Y., Sun, J., Fang, L., Liu, M., Peng, S., Liao, H., Lehmann, J., Zhang, Y., Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors. J. Med. Chem. 55 (2012), 4309–4321, 10.1021/jm300106z.
-
(2012)
J. Med. Chem.
, vol.55
, pp. 4309-4321
-
-
Chen, Y.1
Sun, J.2
Fang, L.3
Liu, M.4
Peng, S.5
Liao, H.6
Lehmann, J.7
Zhang, Y.8
-
54
-
-
84859790482
-
Multifunctional mercapto-tacrine derivatives for treatment of age-related neurodegenerative diseases
-
[54] Wang, Y., Guan, X.-L., Wu, P.-F., Wang, C.-M., Cao, H., Li, L., Guo, X.-J., Wang, F., Xie, N., Jiang, F.-C., Chen, J.-G., Multifunctional mercapto-tacrine derivatives for treatment of age-related neurodegenerative diseases. J. Med. Chem. 55 (2012), 3588–3592, 10.1021/jm300124p.
-
(2012)
J. Med. Chem.
, vol.55
, pp. 3588-3592
-
-
Wang, Y.1
Guan, X.-L.2
Wu, P.-F.3
Wang, C.-M.4
Cao, H.5
Li, L.6
Guo, X.-J.7
Wang, F.8
Xie, N.9
Jiang, F.-C.10
Chen, J.-G.11
-
55
-
-
60549106063
-
Design, synthesis, and evaluation of benzophenone derivatives as novel acetylcholinesterase inhibitors
-
[55] Belluti, F., Piazzi, L., Bisi, A., Gobbi, S., Bartolini, M., Cavalli, A., Valenti, P., Rampa, A., Design, synthesis, and evaluation of benzophenone derivatives as novel acetylcholinesterase inhibitors. Eur. J. Med. Chem. 44 (2009), 1341–1348, 10.1016/j.ejmech.2008.02.035.
-
(2009)
Eur. J. Med. Chem.
, vol.44
, pp. 1341-1348
-
-
Belluti, F.1
Piazzi, L.2
Bisi, A.3
Gobbi, S.4
Bartolini, M.5
Cavalli, A.6
Valenti, P.7
Rampa, A.8
-
56
-
-
84882514623
-
Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease
-
[56] Samadi, A., de la Fuente Revenga, M., Pérez, C., Iriepa, I., Moraleda, I., Rodríguez-Franco, M.I., Marco-Contelles, J., Synthesis, pharmacological assessment, and molecular modeling of 6-chloro-pyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease. Eur. J. Med. Chem. 67 (2013), 64–74, 10.1016/j.ejmech.2013.06.021.
-
(2013)
Eur. J. Med. Chem.
, vol.67
, pp. 64-74
-
-
Samadi, A.1
de la Fuente Revenga, M.2
Pérez, C.3
Iriepa, I.4
Moraleda, I.5
Rodríguez-Franco, M.I.6
Marco-Contelles, J.7
-
57
-
-
84921689816
-
Development of multifunctional, heterodimeric isoindoline-1,3-dione derivatives as cholinesterase and β-amyloid aggregation inhibitors with neuroprotective properties
-
[57] Guzior, N., Bajda, M., Skrok, M., Kurpiewska, K., Lewiński, K., Brus, B., Pišlar, A., Kos, J., Gobec, S., Malawska, B., Development of multifunctional, heterodimeric isoindoline-1,3-dione derivatives as cholinesterase and β-amyloid aggregation inhibitors with neuroprotective properties. Eur. J. Med. Chem. 92 (2015), 738–749, 10.1016/j.ejmech.2015.01.027.
-
(2015)
Eur. J. Med. Chem.
, vol.92
, pp. 738-749
-
-
Guzior, N.1
Bajda, M.2
Skrok, M.3
Kurpiewska, K.4
Lewiński, K.5
Brus, B.6
Pišlar, A.7
Kos, J.8
Gobec, S.9
Malawska, B.10
-
58
-
-
84055217642
-
Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease
-
[58] Bolea, I., Juárez-Jiménez, J., de los Ríos, C., Chioua, M., Pouplana, R., Luque, F.J., Unzeta, M., Marco-Contelles, J., Samadi, A., Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem. 54 (2011), 8251–8270, 10.1021/jm200853t.
-
(2011)
J. Med. Chem.
, vol.54
, pp. 8251-8270
-
-
Bolea, I.1
Juárez-Jiménez, J.2
de los Ríos, C.3
Chioua, M.4
Pouplana, R.5
Luque, F.J.6
Unzeta, M.7
Marco-Contelles, J.8
Samadi, A.9
-
59
-
-
0032458505
-
Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica
-
[59] Kryger, G., Silman, I., Sussman, J.L., Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica. J. Physiol. 92 (1998), 191–194, 10.1016/S0928-4257(98)80008-9.
-
(1998)
J. Physiol.
, vol.92
, pp. 191-194
-
-
Kryger, G.1
Silman, I.2
Sussman, J.L.3
-
60
-
-
0033103478
-
Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs
-
[60] Kryger, G., Silman, I., Sussman, J.L., Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 7 (1999), 297–307, 10.1016/S0969-2126(99)80040-9.
-
(1999)
Structure
, vol.7
, pp. 297-307
-
-
Kryger, G.1
Silman, I.2
Sussman, J.L.3
-
61
-
-
33644811612
-
A new and rapid colorimetric determination of acetylcholinesterase activity
-
[61] Ellman, G.L., Courtney, K.D., Andres, V., Featherstone, R.M., A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7 (1961), 88–95, 10.1016/0006-2952(61)90145-9.
-
(1961)
Biochem. Pharmacol.
, vol.7
, pp. 88-95
-
-
Ellman, G.L.1
Courtney, K.D.2
Andres, V.3
Featherstone, R.M.4
-
62
-
-
84962359573
-
High throughput artificial membrane permeability assay for blood–brain barrier
-
[62] Di, L., Kerns, E.H., Fan, K., McConnell, O.J., Carter, G.T., High throughput artificial membrane permeability assay for blood–brain barrier. Eur. J. Med. Chem. 38 (2003), 223–232, 10.1016/S0223-5234(03)00012-6.
-
(2003)
Eur. J. Med. Chem.
, vol.38
, pp. 223-232
-
-
Di, L.1
Kerns, E.H.2
Fan, K.3
McConnell, O.J.4
Carter, G.T.5
-
63
-
-
0021988656
-
The effects of centrally acting adrenergic agonists on temperature and on explorative and motor behaviour. Relation with effects on quasi-morphine withdrawal behaviour
-
(accessed 04.04.16.)
-
[63] Van der Laan, J.W., Van Veenendaal, W., Voorthuis, P., Weick, G., Hillen, F.C., The effects of centrally acting adrenergic agonists on temperature and on explorative and motor behaviour. Relation with effects on quasi-morphine withdrawal behaviour. Eur. J. Pharmacol. 107 (1985), 367–373 http://www.ncbi.nlm.nih.gov/pubmed/2858393 (accessed 04.04.16.).
-
(1985)
Eur. J. Pharmacol.
, vol.107
, pp. 367-373
-
-
Van der Laan, J.W.1
Van Veenendaal, W.2
Voorthuis, P.3
Weick, G.4
Hillen, F.C.5
-
64
-
-
84863843828
-
Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression
-
[64] Kassai, F., Schlumberger, C., Kedves, R., Pietraszek, M., Jatzke, C., Lendvai, B., Gyertyán, I., Danysz, W., Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression. Behav. Pharmacol. 23 (2012), 397–406, 10.1097/FBP.0b013e3283565248.
-
(2012)
Behav. Pharmacol.
, vol.23
, pp. 397-406
-
-
Kassai, F.1
Schlumberger, C.2
Kedves, R.3
Pietraszek, M.4
Jatzke, C.5
Lendvai, B.6
Gyertyán, I.7
Danysz, W.8
-
65
-
-
84888198516
-
MK-801-induced and scopolamine-induced hyperactivity in rats neonatally treated chronically with MK-801
-
[65] Furuie, H., Yamada, K., Ichitani, Y., MK-801-induced and scopolamine-induced hyperactivity in rats neonatally treated chronically with MK-801. Behav. Pharmacol. 24 (2013), 678–683, 10.1097/FBP.0000000000000003.
-
(2013)
Behav. Pharmacol.
, vol.24
, pp. 678-683
-
-
Furuie, H.1
Yamada, K.2
Ichitani, Y.3
-
66
-
-
85007148366
-
Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813
-
[66] Lavreysen, H., Langlois, X., Ver Donck, L., Nuñez, J.M.C., Pype, S., Lütjens, R., Megens, A., Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813. Pharmacol. Res. Perspect., 3, 2015, e00097, 10.1002/prp2.97.
-
(2015)
Pharmacol. Res. Perspect.
, vol.3
, pp. e00097
-
-
Lavreysen, H.1
Langlois, X.2
Ver Donck, L.3
Nuñez, J.M.C.4
Pype, S.5
Lütjens, R.6
Megens, A.7
-
67
-
-
33748544640
-
Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge
-
[67] Rydberg, E.H., Brumshtein, B., Greenblatt, H.M., Wong, D.M., Shaya, D., Williams, L.D., Carlier, P.R., Pang, Y.-P., Silman, I., Sussman, J.L., Complexes of alkylene-linked tacrine dimers with Torpedo californica acetylcholinesterase: binding of Bis5-tacrine produces a dramatic rearrangement in the active-site gorge. J. Med. Chem. 49 (2006), 5491–5500, 10.1021/jm060164b.
-
(2006)
J. Med. Chem.
, vol.49
, pp. 5491-5500
-
-
Rydberg, E.H.1
Brumshtein, B.2
Greenblatt, H.M.3
Wong, D.M.4
Shaya, D.5
Williams, L.D.6
Carlier, P.R.7
Pang, Y.-P.8
Silman, I.9
Sussman, J.L.10
-
68
-
-
45749135895
-
Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation
-
[68] Camps, P., Formosa, X., Galdeano, C., Gómez, T., Muñoz-Torrero, D., Scarpellini, M., Viayna, E., Badia, A., Clos, M.V., Camins, A., Pallàs, M., Bartolini, M., Mancini, F., Andrisano, V., Estelrich, J., Lizondo, M., Bidon-Chanal, A., Luque, F.J., Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation. J. Med. Chem. 51 (2008), 3588–3598, 10.1021/jm8001313.
-
(2008)
J. Med. Chem.
, vol.51
, pp. 3588-3598
-
-
Camps, P.1
Formosa, X.2
Galdeano, C.3
Gómez, T.4
Muñoz-Torrero, D.5
Scarpellini, M.6
Viayna, E.7
Badia, A.8
Clos, M.V.9
Camins, A.10
Pallàs, M.11
Bartolini, M.12
Mancini, F.13
Andrisano, V.14
Estelrich, J.15
Lizondo, M.16
Bidon-Chanal, A.17
Luque, F.J.18
-
69
-
-
84886947382
-
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids
-
[69] Sun, Y., Chen, J., Chen, X., Huang, L., Li, X., Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids. Bioorg. Med. Chem. 21 (2013), 7406–7417, 10.1016/j.bmc.2013.09.050.
-
(2013)
Bioorg. Med. Chem.
, vol.21
, pp. 7406-7417
-
-
Sun, Y.1
Chen, J.2
Chen, X.3
Huang, L.4
Li, X.5
-
70
-
-
0037413568
-
Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors
-
[70] Savini, L., Gaeta, A., Fattorusso, C., Catalanotti, B., Campiani, G., Chiasserini, L., Pellerano, C., Novellino, E., McKissic, D., Saxena, A., Specific targeting of acetylcholinesterase and butyrylcholinesterase recognition sites. Rational design of novel, selective, and highly potent cholinesterase inhibitors. J. Med. Chem. 46 (2003), 1–4, 10.1021/jm0255668.
-
(2003)
J. Med. Chem.
, vol.46
, pp. 1-4
-
-
Savini, L.1
Gaeta, A.2
Fattorusso, C.3
Catalanotti, B.4
Campiani, G.5
Chiasserini, L.6
Pellerano, C.7
Novellino, E.8
McKissic, D.9
Saxena, A.10
-
71
-
-
26444566295
-
Regioselective alkylation of 3,4-dihydro-2H-pyran by xanthate-mediated free radical nonchain process
-
[71] Torres-Murro, J., Quintero, L., Sartillo-Piscil, F., Regioselective alkylation of 3,4-dihydro-2H-pyran by xanthate-mediated free radical nonchain process. Tetrahedron Lett. 46 (2005), 7691–7694, 10.1016/j.tetlet.2005.09.049.
-
(2005)
Tetrahedron Lett.
, vol.46
, pp. 7691-7694
-
-
Torres-Murro, J.1
Quintero, L.2
Sartillo-Piscil, F.3
-
72
-
-
80054954224
-
Synthesis and structure-activity relationship studies in translocator protein ligands based on a pyrazolo[3,4-b]quinoline scaffold
-
[72] Cappelli, A., Bini, G., Valenti, S., Giuliani, G., Paolino, M., Anzini, M., Vomero, S., Giorgi, G., Giordani, A., Stasi, L.P., Makovec, F., Ghelardini, C., Di Cesare Mannelli, L., Concas, A., Porcu, P., Biggio, G., Synthesis and structure-activity relationship studies in translocator protein ligands based on a pyrazolo[3,4-b]quinoline scaffold. J. Med. Chem. 54 (2011), 7165–7175, 10.1021/jm200770f.
-
(2011)
J. Med. Chem.
, vol.54
, pp. 7165-7175
-
-
Cappelli, A.1
Bini, G.2
Valenti, S.3
Giuliani, G.4
Paolino, M.5
Anzini, M.6
Vomero, S.7
Giorgi, G.8
Giordani, A.9
Stasi, L.P.10
Makovec, F.11
Ghelardini, C.12
Di Cesare Mannelli, L.13
Concas, A.14
Porcu, P.15
Biggio, G.16
-
73
-
-
2142770225
-
Investigations into the mechanism of lactamization of lactones yielding in a novel route to biologically active tryptamine derivatives
-
[73] Decker, M., Nguyen, T.T.H., Lehmann, J., Investigations into the mechanism of lactamization of lactones yielding in a novel route to biologically active tryptamine derivatives. Tetrahedron 60 (2004), 4567–4578, 10.1016/j.tet.2004.03.073.
-
(2004)
Tetrahedron
, vol.60
, pp. 4567-4578
-
-
Decker, M.1
Nguyen, T.T.H.2
Lehmann, J.3
-
74
-
-
0024332001
-
Facile preparation of 2-imino tetrahydrofurans, pyrans and oxepans
-
[74] Alanine, A.I.D., Fishwick, C.W.G., Szantay, C., Facile preparation of 2-imino tetrahydrofurans, pyrans and oxepans. Tetrahedron Lett. 30 (1989), 6571–6572, 10.1016/S0040-4039(01)89024-9.
-
(1989)
Tetrahedron Lett.
, vol.30
, pp. 6571-6572
-
-
Alanine, A.I.D.1
Fishwick, C.W.G.2
Szantay, C.3
-
75
-
-
77949853380
-
Salicylic acid based small molecule inhibitor for the oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)
-
[75] Zhang, X., He, Y., Liu, S., Yu, Z., Jiang, Z.X., Yang, Z., Dong, Y., Nabinger, S.C., Wu, L., Gunawan, A.M., Wang, L., Chan, R.J., Zhang, Z.Y., Salicylic acid based small molecule inhibitor for the oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J. Med. Chem. 53 (2010), 2482–2493, 10.1021/jm901645u.
-
(2010)
J. Med. Chem.
, vol.53
, pp. 2482-2493
-
-
Zhang, X.1
He, Y.2
Liu, S.3
Yu, Z.4
Jiang, Z.X.5
Yang, Z.6
Dong, Y.7
Nabinger, S.C.8
Wu, L.9
Gunawan, A.M.10
Wang, L.11
Chan, R.J.12
Zhang, Z.Y.13
-
76
-
-
84875431627
-
Ligand-optimized homology models of D1 and D2 dopamine receptors: application for virtual screening
-
[76] Kołaczkowski, M., Bucki, A., Feder, M., Pawłowski, M., Ligand-optimized homology models of D1 and D2 dopamine receptors: application for virtual screening. J. Chem. Inf. Model 53 (2013), 638–648, 10.1021/ci300413h.
-
(2013)
J. Chem. Inf. Model
, vol.53
, pp. 638-648
-
-
Kołaczkowski, M.1
Bucki, A.2
Feder, M.3
Pawłowski, M.4
-
77
-
-
84877607189
-
Structural basis for molecular recognition at serotonin receptors
-
[77] Wang, C., Jiang, Y., Ma, J., Wu, H., Wacker, D., Katritch, V., Han, G.W., Liu, W., Huang, X.P., Vardy, E., McCorvy, J.D., Gao, X., Zhou, X.E., Melcher, K., Zhang, C., Bai, F., Yang, H., Yang, L., Jiang, H., Roth, B.L., Cherezov, V., Stevens, R.C., Xu, H.E., Structural basis for molecular recognition at serotonin receptors. Science 340 (2013), 610–614, 10.1126/science.1232807.
-
(2013)
Science
, vol.340
, pp. 610-614
-
-
Wang, C.1
Jiang, Y.2
Ma, J.3
Wu, H.4
Wacker, D.5
Katritch, V.6
Han, G.W.7
Liu, W.8
Huang, X.P.9
Vardy, E.10
McCorvy, J.D.11
Gao, X.12
Zhou, X.E.13
Melcher, K.14
Zhang, C.15
Bai, F.16
Yang, H.17
Yang, L.18
Jiang, H.19
Roth, B.L.20
Cherezov, V.21
Stevens, R.C.22
Xu, H.E.23
more..
-
78
-
-
0043123216
-
GeneSilico protein structure prediction meta-server
-
[78] Kurowski, M.A., Bujnicki, J.M., GeneSilico protein structure prediction meta-server. Nucleic Acids Res. 31 (2003), 3305–3307, 10.1093/nar/gkg557.
-
(2003)
Nucleic Acids Res.
, vol.31
, pp. 3305-3307
-
-
Kurowski, M.A.1
Bujnicki, J.M.2
-
79
-
-
32144432437
-
The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling
-
[79] Arnold, K., Bordoli, L., Kopp, J., Schwede, T., The SWISS-MODEL workspace: a web-based environment for protein structure homology modelling. Bioinformatics 22 (2006), 195–201, 10.1093/bioinformatics/bti770.
-
(2006)
Bioinformatics
, vol.22
, pp. 195-201
-
-
Arnold, K.1
Bordoli, L.2
Kopp, J.3
Schwede, T.4
-
80
-
-
84983032994
-
Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-Hydroxytryptamine-6 ligands
-
US Patent 2005/0101596
-
[80] D.C. Cole, M. Asselin, Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-Hydroxytryptamine-6 ligands, US Patent 2005/0101596, 2005.
-
(2015)
-
-
Cole, D.C.1
Asselin, M.2
|